Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR-mutant NSCLC patient with acquired LMNA-NTRK1 fusion following osimertinib resistance.

Wang, Jiao-Li; Wang, Liu-Sheng; Zhu, Jun-Qi; Ren, Jie; Wang, Di; Luo, Man

Wang, Jiao-Li; Wang, Liu-Sheng; Zhu, Jun-Qi; Ren, Jie; Wang, Di; Luo, Man.

Afiliação

Wang JL; Department of Respiratory Medicine, Affiliated Hangzhou First People's Hospital Zhejiang University School of Medicine Hangzhou China.
Wang LS; Department of Translation Medicine Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine Hangzhou China.
Zhu JQ; The Fourth Clinical Medical College of Zhejiang Chinese Medical University Hangzhou China.
Ren J; Zhejiang University Cancer Centre Hangzhou China.
Wang D; Department of Respiratory Medicine, Affiliated Hangzhou First People's Hospital Zhejiang University School of Medicine Hangzhou China.
Luo M; The Fourth Clinical Medical College of Zhejiang Chinese Medical University Hangzhou China.

Respirol Case Rep ; 10(11): e01054, 2022 Nov.

Article em En | MEDLINE | ID: mdl-36258694

Palavras-chave

EGFRTKI acquired resistance; NTRK fusion; nonsmall cell lung cancer (NSCLC); osimertinib rechallenge

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Respirol Case Rep Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google